Molecular Partners (NASDAQ:MOLN) Lifted to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Molecular Partners (NASDAQ:MOLN) to a strong-buy rating in a report released on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Molecular Partners’ Q3 2024 earnings at ($0.63) EPS, Q4 2024 earnings at ($0.66) EPS, FY2024 earnings at ($2.22) EPS and FY2025 earnings at ($2.29) EPS.

Molecular Partners Stock Down 3.2 %

Shares of NASDAQ:MOLN opened at $4.75 on Monday. The stock has a market cap of $174.24 million, a price-to-earnings ratio of -2.35 and a beta of 0.99. The business has a 50-day moving average price of $5.61 and a 200-day moving average price of $5.28. Molecular Partners has a 52-week low of $3.32 and a 52-week high of $12.70.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Monday, August 26th. The company reported ($0.51) earnings per share (EPS) for the quarter. Molecular Partners had a negative net margin of 730.27% and a negative return on equity of 33.15%. The company had revenue of $1.72 million during the quarter. As a group, equities analysts anticipate that Molecular Partners will post -2.03 EPS for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.